HVIVO PLC

Post-Annual General Meeting Information • Jun 5, 2025

National Storage Mechanism | Additional information

RNS Number : 6521L

hVIVO PLC

05 June 2025

hVIVO plc

("hVIVO" or the "Company")

Result of AGM

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that all resolutions put to shareholders at the Company's Annual General Meeting ('AGM') held earlier today were duly passed.

The voting results of the AGM will be published on the Company website shortly: https://hvivo.com/company-documents/

For further information please contact:

hVIVO plc		+44 (0)20 7756 1300
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)				+44 (0)20 7220 0500
Geoff Nash, Callum Davidson, Trisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales
P eel Hunt L LP (Joint Broker)			+44 (0)20 7418 8900
James Steel, Dr Christopher Golden
Davy (Joint Broker)			+353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings / Lianne Applegarth		+44 (0) 20 7933 8780 or  hvivo@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7407 804 654/   +44 (0)7584 391 303

Notes to Editors

hVIVO plc (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGPKPBPDBKDBAK